DMFs for Buprenorphine HCl and Oxybuynin
Chloride were filed with the US FDA. Resonance
also has a COS for Oxybutynin Chloride from
EDQM.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
March
2010 - New product offering:
Glycopyrrolate and Azasetron were added
to list of products offered by Resonance.
For a full list of products refer to the
product list.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
February
2010 - Marketing partnership in Japan:
Resonance signed an agreement with Toray
International and LSG corporation who will
represent Resonance's services in the Japanese
market for a specific time period.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
December
2010 - New building complete:
Innovation centre building was completed
and commissioned at end of 2009.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
November
2009 - Audit by European customer:
Our quality assurance system was evaluated
for the compliance with ICH Q7 GMP guidance
for the manufacture of Oxybutynin Chloride
(Resonance has COS for the product from
EDQM). Resonance cleared the audit with
some findings.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
July
2009 - Approval for Oxybutynin Chloride:
Resonance's facility in India was approved
for supply of Oxybutynin Chloride by one
of our North American clients. Resonance
also has a COS registered with European
authorities for more than 5 years now.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
Apr
2009 - Opening of the wholly owned subsidiary
in the US:
We opened our US office on April 2, 2009
led by Tushar Gore PhD. The office is located
in Parsippany, New
Jersey and we are looking to
establish a client base in the US and strengthen
the existing base in Europe with efforts
led from this office. Tushar Gore joins
us after several years in pharmaceutical
and chemicals marketing with global companies
such as Novo Nordisk, Sun Chemical and McKinsey
& Company.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
Feb
2009 - Oxybutynin Chloride audit:
Our facilities in India were audited to
evaluate us as a supplier for Oxybutynin
Chloride for a major generic manufacturer.
The initial observations from the report
based on ICH Q7 guidelines were all complied
with and a final review is scheduled in
a few weeks after which Resonance will be
a qualified supplier of Oxybutynin Chloride.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
•
Jan
2009 - Innovation centre Phase I:
We started construction of phase I of the
innovation centre. It is scheduled for completion
in June and the innovation centre is planned
for accommodating R&D activities. With
growing emphasis on Research and Development
activities, we have plans for further growth
of the innovation centre in additional phases.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
